Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 11.1% in August

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 7,000 shares, a growth of 11.1% from the August 15th total of 6,300 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 9,300 shares, the days-to-cover ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Armata Pharmaceuticals in a research note on Thursday, August 15th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC boosted its holdings in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 80.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,777 shares of the company’s stock after acquiring an additional 14,647 shares during the quarter. SeaCrest Wealth Management LLC owned 0.09% of Armata Pharmaceuticals worth $137,000 at the end of the most recent quarter. Institutional investors and hedge funds own 3.57% of the company’s stock.

Armata Pharmaceuticals Stock Performance

Armata Pharmaceuticals stock traded up $0.04 during midday trading on Wednesday, reaching $2.30. 809 shares of the company’s stock were exchanged, compared to its average volume of 13,588. The stock has a market capitalization of $83.21 million, a P/E ratio of -1.01 and a beta of 0.79. Armata Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $4.48.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.13). Research analysts forecast that Armata Pharmaceuticals will post -1.02 earnings per share for the current year.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.